DSC
FLNA

Duncker Streett & Co’s Filana Therapeutics FLNA Stock Holding History

Duncker Streett & Co’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed -$4.9K – 511
2023
Q2 		$4.9K Hold
200
– – ﹤0.01% 434
2023
Q1 		$4.82K Hold
200
– – ﹤0.01% 424
2022
Q4 		$5.91K Hold
200
– – ﹤0.01% 430
2022
Q3 		$8K Hold
200
– – ﹤0.01% 406
2022
Q2 		$6K Buy
+200
New +$5.05K ﹤0.01% 420

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Duncker Streett & Co's FLNA Position: Q3 2023 in Review

Duncker Streett & Co sold out of Filana Therapeutics (FLNA) in Q3 2023, closing a stake of 200 shares — an estimated $4.9K sold.

Duncker Streett & Co first reported a position in FLNA in Q2 2022 and held it in 5 quarters. The position peaked at $8K in Q3 2022. 140 funds tracked by Wall St. Rank hold FLNA as of Q3 2023.

  • Duncker Streett & Co reported no remaining Filana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Duncker Streett & Co sold 200 Filana Therapeutics shares in Q3 2023, an estimated $4.9K.
  • Duncker Streett & Co first reported a position in Filana Therapeutics in Q2 2022 and held it in 5 quarters.
  • Duncker Streett & Co's Filana Therapeutics position peaked at $8K in Q3 2022.
  • 140 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2023.

Based on Duncker Streett & Co's 13F filing for Q3 2023, filed 26 Oct 2023.